$SKYE News

Skye Bioscience Announces Resignation Of CFO John Sharp Effective September 8; Appoints CEO Punit Dhillon As Principal Financial And Accounting Officer

Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move

Skye Bioscience Enters Into Securities Purchase Agreement With Redmile Affiliate For Aggregate Purchase Price Of Up To $22M

Skye Bioscience Inc (SKYE) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Fibrex ...

Skye Bioscience, Inc. (SKYE) Skye Bioscience, Inc. - M&A Call - Slideshow

Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience To Acquire Redx Pharma; Combined Company To Operate As Fibrx Therapeutics With $125M Financing

Skye Bioscience To Switch Listing From Nasdaq Global Market To Nasdaq Capital Market, Effective June 23

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

Skye Bioscience Says Cohort Review Committee Unanimously Approves Opening Second Cohort Of CBeyond Part C Expansion Study

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Q1 EPS $(0.32) Misses $(0.31) Estimate

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience To Highlight Its Approach To Enhancing GLP‑1 Efficacy While Reducing Safety Risks At GLP-1-Based Therapeutics Summit In Boston

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience Treats First Patient In Part C Expansion Study Of CBeyond Phase 2a Trial To Characterize Safety And PK At Exposures To Challenge Peripheral Restriction Of Nimacimab Through IV Administration Over 16 Weeks Of Treatment

Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...

Skye Bioscience shares are trading lower after the company reported a Q4 EPS miss.